Roivant Sciences (ROIV) Cash from Financing Activities (2020 - 2025)

Roivant Sciences has reported Cash from Financing Activities for 6 years, with the latest figure at $203.0 million in Q4 2025.

• For the quarter ending Q4 2025, Cash from Financing Activities rose 119.47% year-over-year to $203.0 million; the trailing twelve-month figure through Dec 2025 stood at -$964.8 million (up 29.08% YoY), and the FY2026 full-year result was $134.2 million, up 111.0% from the prior year.
• Cash from Financing Activities for Q4 2025 stood at $203.0 million, up from $62.6 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $452.0 million in Q4 2023, with the low at -$1.0 billion in Q4 2024.
• Historically, Cash from Financing Activities has averaged -$1.6 million across 5 years, with a median of $62.6 million in 2025.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 2931.66% — and 2024, when it plunged 8935.31%.
• Roivant Sciences' Cash from Financing Activities stood at $305.7 million in 2021, then declined by 5.43% to $289.1 million in 2022, then soared by 56.33% to $452.0 million in 2023, then plunged by 330.68% to -$1.0 billion in 2024, then soared by 119.47% to $203.0 million in 2025.
• The last three Cash from Financing Activities figures came in at $203.0 million (Q4 2025), $62.6 million (Q3 2025), and -$187.8 million (Q2 2025), per Business Quant data.